Universe dying quicker than thought, says new research
The universe is poised to die much faster than previously thought, according to new research by Dutch scientists.
But there's no great need to panic. We still have 10 to the power of 78 years before it happens -- that's a one with 78 zeroes.
However, that is a major revision from the previous estimate of 10 to the power of 1,100 years, notes the research paper from Radboud University, published in the Journal of Cosmology and Astroparticle Physics.
"The final end of the universe is coming much sooner than expected but fortunately it still takes a very long time," said lead author Heino Falcke.
A trio of scientists at Radboud set out to calculate when the most "durable" celestial bodies -- white dwarf stars -- would eventually die out.
They based their calculations on Hawking radiation, named after celebrated British physicist Stephen Hawking.
Hawking postulated in the mid-1970s that black holes leak radiation, slowly dissolving like aspirin in a glass of water -- giving them a finite lifetime.
The Radboud scientists extended this to other objects in the universe, calculating that the "evaporation time" depends on density.
This enabled them to calculate the theoretical dissolution of the longest-lasting body, the white dwarf.
"By asking these kinds of questions and looking at extreme cases, we want to better understand the theory, and perhaps one day, we can unravel the mystery of Hawking radiation," said co-author Walter van Suijlekom.
Humankind needn't worry too much about the end of the universe. Unless we escape planet Earth, we'll be long gone.
Scientists think that our Sun will be too hot for life in about a billion years, boiling our oceans.
In about eight billion years, our star will eventually expand towards the Earth, finally gobbling up our by-then barren and lifeless planet and condemning it to a fiery death.
ric/gil
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
11 hours ago
- Associated Press
Advanced DUT Simulation Technology Reproduces 'Impossible' Galaxies Observed by JWST and Challenges ΛCDM
New simulations reproduce high-redshift galaxies seen by JWST and propose a radical cosmological shift beyond ΛCDM. 'To simulate the universe with mathematical precision is to dismantle myths with data and disprove fiction through gravity.' — Joel Almeida -CEO CURITIBA, PARANá, BRAZIL, June 29, 2025 / / -- A newly released preprint by cosmology researcher and lead developer of the DUT Simulator, Joel Almeida, introduces a groundbreaking computational simulation based on the Dead Universe Theory (DUT), capable of reproducing the observed properties of massive galaxies at redshifts z > 8, including CEERS-1019 and GLASS-z13. These galaxies, detected by the James Webb Space Telescope (JWST), have challenged the predictions of the standard ΛCDM cosmological model. Using DUT's entropy-gradient-driven gravitational collapse, the simulations achieve under 5% accuracy in stellar mass, sub-kpc radius, and formation timescales below 100 million years—outperforming ΛCDM expectations by factors of ~5. Crucially, DUT offers falsifiable predictions and proposes that the universe is not expanding, but retracting within a non-singular, structural black hole. The full simulator is open-source and fully reproducible, available through ExtractoDAO for researchers worldwide. 🛰️ JWST Observes 'Impossible' Galaxies — A New Theory and Quantum Simulator Challenge the Big Bang A new study published as a preprint by researcher Joel Almeida, in collaboration with the scientific startup ExtractoDAO S/A, proposes a bold solution to one of modern cosmology's greatest mysteries: how could massive, compact galaxies have formed so early in the universe? Recent observations from the James Webb Space Telescope (JWST) identified galaxies such as CEERS-1019 (z = 8.67) and GLASS-z13 (z = 13.1), with stellar masses above 10¹⁰ M☉ and cores smaller than 1 kiloparsec—structures that, according to Big Bang and ΛCDM models, should not exist at such early epochs. In response to this enigma, the Dead Universe Theory (DUT) and its computational simulator presented remarkable results: the observed properties of these galaxies were reproduced with up to 5% accuracy, simulating ultrafast star formation (<100 million years) without requiring cosmic inflation or exotic dark matter. 'The simulations show that the universe doesn't need to have emerged from a singular point or to be expanding indefinitely. JWST data can be reinterpreted as evidence of asymmetric gravitational retraction within a larger, stable, non-singular cosmic structure,' says Almeida. The DUT model considers the observable universe to be an entropic bubble embedded in the core of a 'structural black hole'—non-singular, governed by a regularized oscillatory gravitational potential, capable of stabilizing galaxy formation without violating Einstein's equations. The computational tool used, named DarkStructSim™, is fully auditable, reproducible, and operates 100% offline, with future optional integration to quantum clouds such as IBM Quantum. Research Highlights: <5% accuracy in mass and size of z > 8 galaxies Explicit computation of core temperature, gravitational entropy , and cosmological constants ΛCDM refuted under extreme mass and redshift regimes Falsifiability proposed: if no galaxy with z > 12 and M > 10¹⁰ M☉ is observed by end of 2024, DUT will be considered refuted The research is available on Research Square under the title: 📝 Preprint 1.0: JWST High-z Galaxies in the Dead Universe Theory (DUT) Cosmological Framework 👉 Read the full paper: Any researcher can now reproduce the same simulation by downloading the offline code: 🔗 🔗 🔗 About the author: Joel Almeida is a cosmology researcher and founder of ExtractoDAO, a blockchain startup developing scientific technologies based on gravitational simulations, decentralized computing, and secure research infrastructures. 📩 Contact: [email protected] 🔗 ORCID: 0000-0003-4015-7694 🔬 Simulation Platform: Joel almeida ExtractoDAO S.A email us here Visit us on social media: LinkedIn Instagram YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
a day ago
- Yahoo
Archaeology student used a computer model to predict a Roman army camp's location — and it worked
When you buy through links on our articles, Future and its syndication partners may earn a commission. The remains of an ancient Roman army camp have been discovered in the Netherlands, beyond the empire's northern frontier, after researchers used a computer model to pinpoint its location. The "rare" find, at a site called Hoog Buurlo, shows that Roman forces were venturing beyond the Lower German Limes, the boundary that ran along the Rhine roughly 15.5 miles (25 kilometers) south of the camp. "For the Netherlands this is only the fourth Roman temporary camp, so quite a rare find," said Saskia Stevens, an associate professor of ancient history and classical civilization at Utrecht University and the principal investigator of the "Constructing the Limes" project that found the fort. "The fact that it was discovered north of the Lower Germanic Limes, beyond the border of the empire, tells us that the Romans did not perceive the Limes as the end of their Empire," Stevens told Live Science in an email. The fort was likely a temporary marching camp, which troops used for only a few days or weeks, according to a statement from Utrecht University. It's also possible that the camp was a stopover on the way to another camp about a day's march away. Constructing the Limes, a project led by Utrecht University, aims to understand how the Roman border functioned and to unearth temporary Roman camps north of the boundary. Related: Remains of 1,600-year-old Roman fort unearthed in Turkey As a part of the investigation, Jens Goeree, an archaeology student at Saxion University of Applied Sciences, developed a computer program to help predict the location of temporary Roman camps in Veluwe, a region of nature reserves filled with woodlands, grasslands and lakes. This program was based on probability and used data from elevation maps and lidar (light detection and ranging), a technique in which a machine shoots lasers from an aircraft over a site and measures the reflected waves to map the landscape below. "He reconstructed possible routes of the Roman army across the Veluwe area, calculating the number of kilometers an army could travel per day," Stevens said. The program also took into account roads and water availability, and looked for the "typical playing card-shaped camps" that Romans constructed, she said. The computer program didn't disappoint: It led them to the site in Hoog Buurlo within the Veluwe in 2023. In January 2025, the team visited the site to dig archaeological trenches and confirm that the site actually held an ancient fort, according to a statement. The fort was large — 9 acres (3.6 hectares) — and shaped like a rectangle with rounded corners. It had a V-shaped ditch that was 6.6 feet (2 meters) deep, a 10-foot-wide (3 m) earthen wall, and several entrances, Stevens said. However, the team found only a few artifacts at the site, including a fragment of Roman military armor. "The limited number of finds is not surprising as the camp was only in use for a short period of time (days, weeks) and the soldiers would have traveled light," Stevens said. Image 1 of 2 An outline of the newfound fort in the Netherlands. Notice that like many other Roman military forts, it's shaped like a playing card. Image 2 of 2 A lock pin artifact found at the temporary military fort. The small number of finds made it hard to date the camp. But by examining the armor and comparing the newfound site to a camp found in 1922 at another site in the Netherlands, the team dated the newly discovered temporary camp to the second century A.D., Stevens said. RELATED STORIES —1,900-year-old Roman legionary fortress unearthed next to UK cathedral —Possible 'mega' fort found in Wales hints at tension between Romans and Celtics —'Lost' 2nd-century Roman fort discovered in Scotland The finding shows that the Romans "were clearly active beyond the border and saw that area as their sphere of influence," Stevens said. The region north of the limes was likely an important place to take cattle, hides and even enslaved people. The people who lived in the area, the Frisii and the Chamavi, already had ties with the Romans. "The Frisians were generally on good terms with the Romans," as they traded with them, Stevens said. Historical sources mention a treaty in which the Frisians paid taxes in the form of cow hides, and they also provided soldiers for the auxiliary troops and members of Nero's (ruled A.D. 54 to 68) imperial bodyguard.
